Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis

Keiji Ohashi; Michiko Morishita; Haruki Watanabe; Ken Ei Sada; Takayuki Katsuyama; Yoshia Miyawaki; Eri Katsuyama; Mariko Narazaki; Noriko Tatebe; Katsue Watanabe; Tomoko Kawabata; Jun Wada

doi:10.2169/internalmedicine.8683-16

Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis

Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Ken Ei Sada, Takayuki Katsuyama, Yoshia Miyawaki, Eri Katsuyama, Mariko Narazaki, Noriko Tatebe, Katsue Watanabe, Tomoko Kawabata, Jun Wada

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.

Original language	English
Pages (from-to)	2943-2948
Number of pages	6
Journal	Internal Medicine
Volume	56
Issue number	21
DOIs	https://doi.org/10.2169/internalmedicine.8683-16
Publication status	Published - 2017

Keywords

Antineutrophil cytoplasmic antibody-associated vasculitis
Diabetes insipidus
Etanercept
Hypertrophic pachymeningitis
Rituximab

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.8683-16

Fingerprint Dive into the research topics of 'Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis'. Together they form a unique fingerprint.

Cite this

Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. / Ohashi, Keiji; Morishita, Michiko; Watanabe, Haruki; Sada, Ken Ei; Katsuyama, Takayuki ; Miyawaki, Yoshia; Katsuyama, Eri; Narazaki, Mariko; Tatebe, Noriko; Watanabe, Katsue; Kawabata, Tomoko; Wada, Jun.

In: Internal Medicine, Vol. 56, No. 21, 2017, p. 2943-2948.

Research output: Contribution to journal › Article › peer-review

Ohashi, Keiji ; Morishita, Michiko ; Watanabe, Haruki ; Sada, Ken Ei ; Katsuyama, Takayuki ; Miyawaki, Yoshia ; Katsuyama, Eri ; Narazaki, Mariko ; Tatebe, Noriko ; Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun. / Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. In: Internal Medicine. 2017 ; Vol. 56, No. 21. pp. 2943-2948.

@article{878aee86932b43a98e8384edc811540d,

title = "Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis",

abstract = "We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.",

keywords = "Antineutrophil cytoplasmic antibody-associated vasculitis, Diabetes insipidus, Etanercept, Hypertrophic pachymeningitis, Rituximab",

author = "Keiji Ohashi and Michiko Morishita and Haruki Watanabe and Sada, {Ken Ei} and Takayuki Katsuyama and Yoshia Miyawaki and Eri Katsuyama and Mariko Narazaki and Noriko Tatebe and Katsue Watanabe and Tomoko Kawabata and Jun Wada",

note = "Funding Information: This work was supported by the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan under Grant <nannti-ippann-044>.",

year = "2017",

doi = "10.2169/internalmedicine.8683-16",

language = "English",

volume = "56",

pages = "2943--2948",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "21",

}

TY - JOUR

T1 - Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis

AU - Ohashi, Keiji

AU - Morishita, Michiko

AU - Watanabe, Haruki

AU - Sada, Ken Ei

AU - Katsuyama, Takayuki

AU - Miyawaki, Yoshia

AU - Katsuyama, Eri

AU - Narazaki, Mariko

AU - Tatebe, Noriko

AU - Watanabe, Katsue

AU - Kawabata, Tomoko

AU - Wada, Jun

N1 - Funding Information: This work was supported by the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan under Grant <nannti-ippann-044>.

PY - 2017

Y1 - 2017

N2 - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.

AB - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.

KW - Antineutrophil cytoplasmic antibody-associated vasculitis

KW - Diabetes insipidus

KW - Etanercept

KW - Hypertrophic pachymeningitis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85032731778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032731778&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.8683-16

DO - 10.2169/internalmedicine.8683-16

M3 - Article

C2 - 28943556

AN - SCOPUS:85032731778

VL - 56

SP - 2943

EP - 2948

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 21

ER -